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TURKISH CULTURAL ADAPTATION AND VALIDATION OF GLASGOW 
HEALTH STATUS INVENTORY
Oksuz E, Malhan S, Tekin R, Yilmaz F, Baytar S
Baskent University, Ankara, Turkey
OBJECTIVES: The Glasgow Health Status Inventory, (GHSI) measures the effect of 
a health problem on the quality of life of a person and allows cross-comparison among 
many health conditions, among different health interventions, and among demo-
graphic and cultural subgroups. The GHSI contains 18 health status questions, which 
ask speciﬁ c questions about how the health problem has affected their quality of life. 
This study aims to adapt the GHSI into Turkish culture and check the reliability and 
validity of the inventory culturally. METHODS: The original instrument was trans-
lated and back translated by two independent translators. a small sample consisting 
of 40 people was used to check the initial comprehension and factibility. Cronbach’s 
Alfa was used to assess reliability and factor analysis to assess dimensionality. The 
EuroQol questionnaire and corresponding Visual Analogue Scales were used for 
concurrent validity. RESULTS: A total of 163 people participated in this study. 52% 
of them were female, 48% of them were male. Mean age was 24.3. The internal 
consistency coefﬁ cient (Cronbach’s alpha) of GHSI was 0.86. Factor analysis of the 
scale revealed that it was composed of four factors with Eigenvalues >1.0, accounting 
for 62.2 % of the total variance. Correlations were moderate with EuroQol and VAS. 
CONCLUSIONS: The culturally adapted GHSI has good validity and reliability, 
making it a potentially useful outcome measure in the determining the effect of health 
problems on the quality of life of people in Turkey.
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A CONCEPTUAL FRAMEWORK FOR A PATIENT REPORTED 
OUTCOMES MEASURE OF ATTITUDES TOWARD COMPLEMENTARY 
AND ALTERNATIVE MEDICINE IN MENOPAUSE
Bunsiriluck S, Williamson EM, Donyai P
Reading University, Reading, UK
OBJECTIVES: Menopause may cause hot ﬂ ashes, night sweats, mood swings and 
other symptoms. Although hormone replacement therapy (HRT) is prescribed in 
severe cases, it is not suitable for all women, and increasing numbers of women refuse 
or discontinue HRT because of side effects, or real or perceived health risks. The use 
of complementary and alternative medicine (CAM) in menopause has been increasing, 
with women perceiving CAM as safer than HRT, but this is not supported by clinical 
evidence. Biased decisions occur when an individual’s cognition is affected by factors 
that include attitudes, preferences, and moods. Cognitive bias affecting women’s 
perception of CAM can impact on decisions and ultimately CAM usage in the meno-
pause. Yet, no validated questionnaire exists to measure attitudes towards CAM in 
menopause, in line with accepted patient reported outcome (PRO) methodology. Our 
aim was to develop a conceptual framework of attitudes to CAM in the menopause 
to inform the development of a PRO tool. METHODS: A systematic review of the 
literature was conducted April-May 2010 using Medline and PsycINFO databases 
with the MESH terms attitude, menopause, complementary therapy, and perception. 
a total of 122 papers were retrieved, with 91 excluded on the basis of abstract review 
and 13 after full-text analysis, resulting in 19 studies suitable for inclusion. The papers 
were analyzed in line with qualitative review methodology to produce a number of 
themes that were later grouped together to produce the dominant categories. 
RESULTS: A conceptual framework was developed to reﬂ ect attitudes to CAM in the 
menopause. The dominant categories of perception related to menopausal symptoms, 
optimism about CAM, pessimism about HRT, cure-control with CAM, and relation-
ship with physician. CONCLUSIONS: This research has identiﬁ ed key domains rel-
evant to women’s attitudes towards CAM in the menopause, from which a relevant 
PRO instrument could be developed.
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USING A GENERALIZED ADDITIVE MODEL TO EXAMINE THE 
RELATIONSHIP BETWEEN BODY MASS INDEX AND HEALTH-RELATED 
QUALITY OF LIFE IN THE ELDERLY POPULATION—RESULTS FROM 
THE POPULATION-BASED GERMAN KORA-AGE STUDY
Hunger M, Thorand B, Döring A, Peters A, Schunk M, Holle R
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OBJECTIVES: Numerous cross-sectional studies reported that high body mass index 
(BMI) is associated with poorer health-related quality of life (HRQL), while only few 
studies also provide evidence for impaired HRQL in underweight individuals. Our 
objective was to investigate the nonlinear relationship between BMI and HRQL in an 
elderly general population sample using semiparametric regression methods. 
METHODS: We analyzed data from 4562 individuals aged 65 years or older, living 
in the region of Augsburg, Southern Germany. The data come from the KORA-Age 
study which is based on a postal follow-up of individuals who participated in the 
population-based MONICA/KORA surveys S1-S4. Health-related quality of life was 
measured using the German EQ-5D index. For our multivariable regression analyses, 
we used a generalized additive model (GAM) to estimate the functional form of the 
relationship between BMI and HRQL after adjusting for confounding factors. 
RESULTS: We found a signiﬁ cant nonlinear (inverse U-shaped) relationship between 
BMI and HRQL after adjusting for gender, age, sociodemographic factors and comor-
bid conditions. The maximum HRQL was observed at a BMI of about 25 kg/m2. Our 
estimates indicate that going from a BMI of 25 to 35 is associated with a EQ-5D 
utility loss of about 5.2 units (corresponding to 0.28 of standard deviation). On the 
other hand, underweight individuals with a BMI of 18 had an average impairment of 
5.8 units compared to a BMI of 25. Subgroup analyses showed that the inverse 
U-shaped relationship is more pronounced in individuals ≥75 years than in individuals 
aged 65–74 years. In particular, the effect of low BMI on HRQL is more important 
in the older age group. CONCLUSIONS: Generalized additive models are an adequate 
method to estimate the nonlinear relationship between BMI and HRQL in the elderly 
population. With increasing age, low BMI has similar impairments in HRQL as 
overweight.
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IDENTIFYING APPROPRIATE COMPARISON GROUPS IN GLOBAL 
PREGNANCY REGISTRIES
Albano JD1, Roberts SS2, Brown VD3
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BACKGROUND: Pregnancy exposure registries are valuable for studying the terato-
genicity of drugs used in the post-marketing setting. However, their limited sample 
size and potential for selection bias can make data interpretation challenging. While 
enrolling an internal comparison group is ideal, this is often not feasible. To ease these 
limitations, pregnancy registries commonly use a population-based background rate 
as the primary comparison group. OBJECTIVES: The objectives of this research are 
to evaluate appropriate population-based birth defect surveillance systems, cohorts, 
and other studies from a variety of geographic areas and to systematically assess their 
utility as a comparison group for global pregnancy exposure registries. RESULTS: 
Among the 14 studies evaluated, study designs include observational cohort studies, 
case control studies, population-based surveillance registries, and population-based 
active surveillance systems. Catchment areas are somewhat diverse geographically and 
range in scope from a metropolitan city, single state/province, or individual country, 
to multi-national/multi-continental networks of organizations contributing to a single 
data source. All identiﬁ ed studies have been ongoing for at least a decade. Studies 
range in size from several thousand participants in total to more than 1 million par-
ticipants enrolled annually. Data reporters vary and include patients, physicians, and 
other health care personnel. Some studies ascertain infant outcome and birth defect 
status at the time of birth only, while others involve pediatricians and include follow-
up for one to several years. CONCLUSIONS: There are many potential sources of 
comparison data for overall birth defect rates; however, the sources vary greatly in 
design, data collection methods, birth defect coding systems, clinical review proce-
dures, and equation for calculating birth defect prevalence rate. Utilizing a population-
based background rate can be useful, but care should be taken in selecting an 
appropriate comparison group. The differences between the individual pregnancy 
registry and the population-based comparator should be evaluated and recognized. 
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OBJECTIVES: Pramipexole, Rasagiline, and Ropinirole are approved for monother-
apy in early PD. Understanding the comparative safety proﬁ les of these products can 
be important information to choose an optimal therapy. As no direct comparisons of 
the safety proﬁ le of these products are available, our objective was to perform an 
indirect comparison of Adverse Events (AEs) and Dropout Rates (DRs). METHODS: 
Articles were selected and reviewed via Cochrane Guidelines. Placebo-controlled ran-
domized clinical trials were eligible for review. Data collected for analysis included 
total AEs, Cognitive, Gastrointestinal (GI), and Sleep/Fatigue AE categories and 
dropout rates. We used indirect meta-analysis to calculate the pooled Relative Risk 
(RR) of each product against placebo, and then used pairwise comparisons. Frequen-
tist and Bayesian methods were used to compare sensitivity of ﬁ ndings. RESULTS: 
208 studies were identiﬁ ed and reviewed, 6 were determined eligible via established 
criterion. The RRs and [95%CIs] from the ﬁ xed-effects model for Rasagiline, Prami-
pexole, and Ropinirole respectively were total AEs: .97 [.87, 1.07], 1.05 [1.00, 1.1], 
1.07 [1.00, 1.14]; Cognitive: .78 [.43, 1.44], 5.56 [2.35, 13.13], 1.56 [.83, 2.94]; GI: 
.9 [.49, 1.63], 2.00 [1.57, 2.53], 2.43 [1.81, 3.27]; Sleep/Fatigue: .84 [.53, 1.35], 1.63 
[1.35, 1.97], 3.24 [2.08, 5.05]; and DR: .60 [.39, .91], 1.01 [.66, 1.56], 1.77 [1.14, 
2.76]. AEs were no worse than placebo for all Rasagiline AEs and for Ropinirole 
cognitive AEs. DRs for Rasagiline were signiﬁ cantly lower than placebo. Rasagiline 
had the lowest RRs with ≥90% conﬁ dence for all categories. Results were comparable 
across statistical models tested. CONCLUSIONS: This indirect treatment comparison 
suggests that subjects with early PD treated with Rasagiline have less risk for adverse 
events and treatment dropouts than patients treated with Pramipexole or Ropinirole. 
Ropinirole exhibits the highest risk for GI AEs, Sleep/Fatigue AEs and DRs, while the 
risk for Cognitive AEs is higher for Pramipexole.
